Advertisement
Advertisement
U.S. Markets close in 5 hrs 2 mins
Advertisement
Advertisement
Advertisement
Advertisement

Veru Inc. (VERU)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
14.32+1.30 (+10.02%)
As of 10:58AM EDT. Market open.
Advertisement

Veru Inc.

48 NW 25th Street
Suite 102
Miami, FL 33127
United States
305 509 6897
https://www.verupharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees252

Key Executives

NameTitlePayExercisedYear Born
Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.Chairman, Pres & CEO1.43MN/A1961
Dr. Harry Fisch F.A.C.S., M.D.Vice Chairman & Chief Corp. Officer648.12kN/A1959
Ms. Michele GrecoCFO & Chief Admin. Officer659.62kN/A1959
Dr. K. Gary Barnette Ph.D.Chief Scientific Officer636.7kN/A1968
Mr. Samuel FischExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Michael J. PurvisExec. VP, Gen. Counsel & Corp. Strategy and Sec.N/AN/AN/A
Mr. Kevin J. Gilbert CPA, J.D.Exec. VP of Corp. Devel.N/AN/AN/A
Dr. Robert H. Getzenberg Ph.D.Exec. VP for Medical AffairsN/AN/AN/A
Dr. Domingo RodriguezExec. VP of Clinical OperationsN/AN/A1962
Mr. Gary Bird Ph.D.Sr. VP of Quality OversightN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Corporate Governance

Veru Inc.’s ISS Governance QualityScore as of May 1, 2022 is 6. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement